Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906434 | 0.98 | HRH3 (0.53) | HRH3DGAT1LTA4HCYP2D6CYP2C19 | |
| SCHEMBL29705162 | 0.96 | HRH3 (0.55) | HRH3DGAT1LTA4HCYP2D6CYP2C19 | |
| SCHEMBL18632015 | 0.96 | HRH3 (0.55) | HRH3DGAT1LTA4HCYP2D6CYP2C19 | |
| SCHEMBL30192619 | 0.92 | DGAT1 (0.47) | HRH3DGAT1ALDH1A1 | |
| SCHEMBL4111762 | 0.91 | DGAT1 (0.49) | HRH3DGAT1LTA4HCYP2D6CYP2C19 | |
| SCHEMBL9906435 | 0.91 | DGAT1 (0.47) | HRH3DGAT1CYP2D6ALDH1A1 | |
| SCHEMBL17531642 | 0.90 | DGAT1 (0.48) | HRH3DGAT1LTA4HCYP2D6CYP2C19 | |
| SCHEMBL20844051 | 0.89 | DGAT1 (0.45) | HRH3DGAT1ALDH1A1 | |
| SCHEMBL7879463 | 0.84 | DGAT1 (0.47) | DGAT1LTA4H | |
| SCHEMBL20843841 | 0.84 | DGAT1 (0.43) | HRH3DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2023-09-14 | — | — | US | disclosed |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2023-09-14 | — | — | US | disclosed |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2023-09-14 | — | — | US | disclosed |
| US-11613539-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-03-28 | — | — | US | disclosed |
| US-11613539-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-03-28 | — | — | US | disclosed |
| EP-3683220-B1 | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1-ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF HUNTINGTON'S DISEASE | ASTRAZENECA AB (SE) | 2022-04-13 | — | — | EP | disclosed |
| US-20210147416-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| US-20210147416-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| US-10882858-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2021-01-05 | — | — | US | disclosed |
| US-10882858-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2021-01-05 | — | — | US | disclosed |
| EP-3140303-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2017-03-15 | — | — | EP | disclosed |
| US-20160368920-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2016-12-22 | — | — | US | disclosed |
| US-20160368920-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2016-12-22 | — | — | US | disclosed |
| US-20160368920-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2016-12-22 | — | — | US | disclosed |
| US-9428503-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating Cancer | ASTRAZENECA AB (SE) | 2016-08-30 | — | — | US | disclosed |
| US-9428503-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating Cancer | ASTRAZENECA AB (SE) | 2016-08-30 | — | — | US | disclosed |
| US-20150336952-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2015-11-26 | — | — | US | disclosed |
| US-20150336952-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2015-11-26 | — | — | US | disclosed |
| US-20150336952-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2015-11-26 | — | — | US | disclosed |
| WO-2015170081-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2015-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147416-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | HRH3 2233/4885DGAT1 4505/4885LTA4H 4790/4885 |
| US-10882858-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ATM, BRCA1, CHEK2 | HRH3 2208/4885DGAT1 4538/4885LTA4H 4780/4885 |
| US-11613539-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ATM, BRCA1, CHEK2 | HRH3 2082/4885DGAT1 4514/4885LTA4H 4765/4885 |
| US-20160368920-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, CHEK2, CHEK1 | HRH3 2231/4885DGAT1 4551/4885LTA4H 4773/4885 |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | HRH3 2082/4885DGAT1 4514/4885LTA4H 4765/4885 |
| US-20150336952-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, CHEK2, CHEK1 | HRH3 2231/4885DGAT1 4551/4885LTA4H 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.